RPG Life Sciences fixes record date for dividend
RPG Life Sciences announced its Nineteenth Annual General Meeting for July 23, 2026, via video conferencing, with a record date of July 16, 2026, for dividend entitlement. The company reported an 8.3% revenue growth to ₹707.52 crores for FY26, driven by a 13.8% rise in Domestic Formulations, while International Formulations saw a 6.7% decline.

*this image is generated using AI for illustrative purposes only.
RPG Life Sciences Limited has announced the schedule for its Nineteenth Annual General Meeting (AGM), scheduled for Thursday, July 23, 2026, at 3.00 p.m. IST via Video Conferencing. The company has fixed Thursday, July 16, 2026, as the record date to determine the eligibility of members entitled to receive the dividend, subject to shareholder approval. The remote e-voting facility will be available from Monday, July 20, 2026, at 09:00 a.m. to Wednesday, July 22, 2026, at 05:00 p.m.
Financial Performance
The company reported total income of ₹733.06 crores for the year ended March 31, 2026, compared to ₹666.11 crores in the previous year. Revenue from operations stood at ₹707.52 crores, registering a growth of 8.3%. Profit for the year after tax was ₹115.17 crores, while EBITDA margins were maintained at 24.4%. The balance sheet remained strong with cash reserves of approximately ₹275 crores.
| Metric | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Total Income (₹ crores) | 733.06 | 666.11 |
| Profit before tax (₹ crores) | 154.20 | 232.88 |
| Profit for the year (₹ crores) | 115.17 | 183.24 |
| Basic EPS (₹) | 69.64 | 110.80 |
Segment and Operational Highlights
Domestic Formulations revenue grew 13.8% year-on-year to ₹483.5 crores, outperforming the Indian Pharmaceutical Market growth of 8.6%. International Formulations reported a de-growth of 6.7% to ₹123.43 crores, while API sales increased 5.3% to ₹95.06 crores. The API plant is now fully operational following restoration post the fire incident. The Board has recommended a final dividend of ₹24 per equity share (300%) for FY 2025-26.
Historical Stock Returns for RPG Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.41% | -2.54% | +24.33% | +30.97% | +12.44% | +528.86% |
What strategies will the company implement to reverse the de-growth in the International Formulations segment?
How does the company plan to utilize its strong cash reserves of ₹275 crores for future expansion or acquisitions?
Will the operational restoration of the API plant lead to increased capacity or new product launches in the coming year?


































